Concord Drugs (538965)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

When I look at Concord Drugs, the figures force me to be skeptical. The stock trades at ₹38.84 against a book value of ₹35.75, so the price-to-book is just 1.09. That gives a superficial comfort: I am paying roughly book value for a pharmaceutical business. But Ben Graham taught me that a good price is not enough; the business must earn a decent return on those assets. Here the return on equity is -19.57%, and the latest quarter shows sales of ₹17 Cr with net profit of ₹0 Cr. In other words, shareholders are not earning anything; the company is destroying book value. The reported sales growth of 56.36% looks strong, but profit growth is 0.00%, so growth is not reaching the bottom line. A P/E of 149.06 and a PEG of 2.64 on zero earnings growth are meaningless except as a warning. ROCE of 4.73% may be barely positive, but that is unlikely to cover the true cost of capital. The Piotroski F-Score of 4 out of 9 confirms a mediocre financial picture. I also notice debt/equity is not available, and promoter holding is not available, so this is not a situation where I can do deep due diligence with confidence. The current price is below the 52-week low of ₹49, and there is no dividend to compensate me for waiting. This is not a fast grower; it is a speculative turnaround. I would need to see margins and profits appear, ROE turn positive, and debt clarity before buying. Until then, the asset cushion at P/B 1.09 gives limited protection, but only if the assets are worth what the books say.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer